Parabilis Sets New Biotech IPO Bar with 670 Million Dollar Debut
Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an upsized Nasdaq offering that tops even this year’s prior record from Kailera Therapeutics. For investors, the size of the deal signals both strong institutional demand and a thawing IPO window for high‑quality drug developers after last year’s drought.
IPO size, pricing and ticker
Parabilis Medicines, formerly known as FogPharma, priced 33.5 million shares of common stock at 20 dollars each, generating 670 million dollars in gross proceeds for what Fierce Biotech and other outlets describe as the largest biotech IPO on record. Underwriters also hold a 30‑day option to buy up to 5 million additional shares at the IPO price, which could push proceeds higher if fully exercised.
The final raise overshot multiple earlier plans. Parabilis initially targeted around 413 million dollars at a midpoint of 18 dollars per share, then upsized to a potential 636.8 million dollars before ultimately landing at 670 million dollars with a higher share count and a 20 dollar price. The company is listing on Nasdaq under the ticker symbol “PBLS.”
How it compares to prior biotech listings
Parabilis’ IPO surpasses the recent 625 million dollar offering by obesity‑focused Kailera Therapeutics, which had briefly held the record for the largest biotech IPO. It also continues a run of larger, late‑stage offerings that suggest investors are once again willing to fund select drug developers at scale, particularly those with differentiated platforms and partnerships.
The company’s pipeline centers on peptide‑based cancer therapies, and it recently signed a collaboration with Regeneron Pharmaceuticals, which helped build credibility ahead of the IPO. With PBLS now public and well‑funded, the focus shifts from deal size to execution—meeting clinical milestones, managing cash, and navigating an increasingly competitive oncology landscape.
